Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

investorenquiries@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

Cancer Therapeutics Research

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

December 21, Epichem Awarded DNDi Extension

201221_EpichemDNDi

Category: News & Announcements 2020By PharmAust 21/12/2020

Related posts

December 31, Top 20 Shareholders
04/01/2021

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials
23/12/2020

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
22/12/2020

December 4, Issued Capital
04/12/2020

November 30, Top 20 Shareholders
01/12/2020

November 5, AGM Results
05/11/2020

Recent Articles

Data from Canine Oncology Study Supports Progression to Registration Studies
19/10/2023
Chief Executive Officer Appointment
28/08/2023
Additional Phase 1 data suggest MPL may inhibit MND
22/08/2023
Cohort 3 Pharmacokinetics in MND Patients Completed
09/08/2023

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @pharmaust ·

10h

PharmAust on global pharma radar post-Phase I MND trial; could divest vet program – CEO | ION Analytics | @Mergermarket https://mergermarket.ionanalytics.com/content/1003685710

Reply on Twitter 1732011434392035701 Retweet on Twitter 1732011434392035701 Like on Twitter 1732011434392035701 2 Twitter 1732011434392035701

PharmAust @pharmaust ·

4 Dec

PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
Via - @PharmaDispatch

Reply on Twitter 1731800187344204140 Retweet on Twitter 1731800187344204140 Like on Twitter 1731800187344204140 8 Twitter 1731800187344204140

Retweet on Twitter PharmAust Retweeted

PharmAust @pharmaust ·

1 Dec

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation via @themarketherald

Reply on Twitter 1730432667206946849 Retweet on Twitter 1730432667206946849 3 Like on Twitter 1730432667206946849 8 Twitter 1730432667206946849

Load More

Copyright © 2023 PharmAust. All rights reserved.

nil

Website Design & Digital Marketing Perth by Total Click Solutions